Datapoint: AbbVie’s Rinvoq Chalks Up Atopic Dermatitis Win

The FDA on Jan. 14 approved AbbVie’s Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children 12 and older who have not responded to previous treatments. The JAK inhibitor was approved for daily use in both its 15mg and 30mg strengths, which could give it a competitive edge. For the treatment of rheumatoid arthritis, Rinvoq currently holds covered or better status for 96% of all insured lives under the pharmacy benefit. 37% of covered lives have preferred access to Rinvoq.

SOURCE: MMIT Analytics, as of 1/19/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: HealthPartners to Launch Insurance Products With Avera

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 19

Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today